A 2018 meta-analysis compared the data on toxicity profiles of PD-1 and PD-L1 inhibitors from 23 studies that occurred between 2013 and 2016 (PD-1, n = 3284; PD-L1, n = 2460).A near-significant trend revealed irAES to be more common with PD-1 vs.
← all excerpts
Cancer immunotherapy experience in the Integral Oncology Centre "Diana Laura Riojas de Colosio", Médica Sur Hospital.
1
—
—